Unibest

Pharmaceutical intermediates

Gilteritinib Intermediates

2 pharmaceutical intermediates for Gilteritinib. Indication: Leukemia, Myeloid, Acute.

提交项目All intermediates

About Gilteritinib

Originator
Astellas Pharma Inc.
Indication
Leukemia, Myeloid, Acute
Approved Date
11/28/2018
DS/DP
07/28/2030

Available intermediates

2 intermediates currently listed for Gilteritinib. Request specifications, documentation or a quotation for any item below.

Gilteritinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
Methyl-4-(4-piperidyl)piperazineTrihydrochloride1621519-77-4//
1-(1-(2-methoxy-4-nitrophenyl)piperidin-4-yl)-4-methylpiperazine254058-33-7//

Other programs under G

GadobutrolGepotidacin

Building toward Gilteritinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →